Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03182374
Recruitment Status : Active, not recruiting
First Posted : June 9, 2017
Last Update Posted : January 22, 2020
Information provided by (Responsible Party):
Zimmer Biomet

Brief Summary:
This is a two-phase multicenter, double-blind, randomized, prospective evaluation of intra-articular injection(s) comparing APS to intra-articular HA injection(s). The maximum study duration for each subject will be 62 months; 60 months from treatment to last follow-up, and two additional months if the maximum visit window is realized. A total of 246 patients will be enrolled. These patients will meet specific inclusion and exclusion criteria, but can be generally characterized as patients with painful unilateral knee OA who have been unable to achieve satisfactory pain relief with previous conservative OA treatment.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Device: nSTRIDE APS Device: Synvisc-One Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 246 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: During the long-term follow-up phase (12 - 60 months), subjects may also elect to cross over to the other treatment arm and receive additional injections of the other treatment as frequently as needed, provided they did not experience any significant clinical concerns after previous treatment administrations and are benefiting from it, as determined by the investigator. Subjects may only cross over from their originally assigned treatment group to the other treatment group one time during the study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: This is a double-blind study where subjects and evaluators are blinded to treatment up to 12-months. During the long-term follow-up phase (12 - 60 months), only subjects will be blinded to the study treatment resulting in single-blind design following 12-month follow-up time point.
Primary Purpose: Treatment
Official Title: A Two-Phase, Multicenter, Randomized Study Comparing Autologous Protein Solution With Hyaluronic Acid Intra Articular Injections in Patients With Knee Osteoarthritis
Actual Study Start Date : July 14, 2017
Actual Primary Completion Date : September 30, 2019
Estimated Study Completion Date : September 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Active Comparator: nSTRIDE APS
The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
Intra-articular injection
Other Name: Autologous Protein Solution

Active Comparator: Synvisc-One
Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
Device: Synvisc-One
Intra-articular injection
Other Name: hylan G-F 20

Primary Outcome Measures :
  1. Comparing Autologous Protein Solution (APS) with Hyaluronic Acid (HA) Intra Articular Injections [ Time Frame: 12 months ]
    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) LK 3.1 pain score

Secondary Outcome Measures :
  1. NRS pain scale [ Time Frame: 12 months ]
    Change in pain as measured by NRS pain scale

  2. OMERACT-OARSI [ Time Frame: 12 months ]
    Percentage of subjects achieving clinical success as defined by OMERACT-OARSI Responder Criteria

  3. WOMAC LK 3.1 [ Time Frame: 12 months ]
    Change in WOMAC LK 3.1 function, stiffness subscale and overall scores

  4. EQ-5D [ Time Frame: 12 months ]
    Change in quality of life

  5. Adverse Events (AEs) [ Time Frame: 12 months ]
    Occurrence of AEs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female at least 18 years of age at time of screening.
  • Willingness and ability to comply with study procedures and visit schedules and able to follow oral and written instructions.
  • A standing knee radiograph showing a K-L grade of 2 to 4
  • Body mass index ≤ 40 kg/m2
  • A qualifying WOMAC LK 3.1 pain subscale total score
  • Signed an ethics committee-reviewed and approved informed consent form.

Exclusion Criteria:

  • Presence of clinically observed active infection in the index knee
  • Presence of symptomatic OA in the non-study knee at screening
  • Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; HIV, viral hepatitis; chondrocalcinosis, Paget's disease, or villonodular synovitis
  • Diagnosed with leukemia, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment
  • Presence of venous or lymphatic stasis in the index leg
  • A history of local anesthetic allergy
  • Previously documented failed treatment with nSTRIDE APS or Synvisc One

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03182374

Layout table for location information
AZ Monica
Antwerp, Belgium
The Parker Institute, Frederiksberg Hospital
Copenhagen, Denmark
Praxiskliniek für Unfallchirurgie und Orthopädie
Eisenach, Germany
Straubing, Germany
Rizzoli Orthopedic Institute
Bologna, Italy
The Istituto Clinico Humanitas
Milano, Italy
Maastricht UMC+
Maastricht, Netherlands
Oslo University Hospital - Olympiatoppen
Oslo, Norway
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain
Ospedale Regionale di Lugano
Lugano, Switzerland
Yildirim Beyazit University, School of Medicine
Ankara, Turkey
United Kingdom
Gloucestershire Hospitals NHS Foundation Trust
Cheltenham, United Kingdom
Royal Infirmary of Edinburgh - NHS Lothian
Edinburgh, United Kingdom
Sponsors and Collaborators
Zimmer Biomet
Layout table for investigator information
Principal Investigator: Elizaveta Kon Humanitas University Hospital
Layout table for additonal information
Responsible Party: Zimmer Biomet Identifier: NCT03182374    
Other Study ID Numbers: APSS-66-00
First Posted: June 9, 2017    Key Record Dates
Last Update Posted: January 22, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Zimmer Biomet:
Autologous Protein Solution (APS)
Intra-articular Injection
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Protective Agents
Physiological Effects of Drugs